Wednesday, July 26, 2017
NIH-funded research could aid drug development for the condition.
Scientists at the University of Florida have discovered a new method of observing the brain changes caused by Parkinsons disease, which destroys neurons important for movement. The development suggests that fluid changes in a specific brain area could provide a way to track that damage. The study, published in the journal Brain, was supported by the NIHs National Institute of Neurological Disorders and Stroke (NINDS).
By finding a new way to detect and track how Parkinsons affects the brain, this study provides an important tool for assessing whether a drug might slow or stop those changes and keep symptoms from getting worse, said NINDS Program Director Daofen Chen, Ph.D.
The researchers, led by David Vaillancourt, Ph.D., a professor of applied physiology and kinesiology at the University of Florida in Gainesville, FL, used a form of MRI that differentiates between water contained in brain cells and free water outside of cells. Their analysis focused on the substantia nigra, a brain structure where Parkinsons disease kills neurons that use the chemical dopamine to communicate with other cells. The results showed that the amount of free water in that brain area stayed the same over the course of a year in healthy individuals but increased in early-stage Parkinsons patients during that period and increased further over the next three years. This confirms and expands on a prior study by the same group that measured free water over just one year. The new findings also revealed the increase in free water was linked to worsening symptoms.
The amount of free water doesnt just change over one year it keeps progressively increasing, which suggests that its tracking the progressive degeneration of neurons, said Dr. Vaillancourt.
The researchers used a scale to evaluate patients movement problems, with Stage One on the scale being the least severe and Stage Five being the most advanced. Patients who moved up a stage on the scale during the four years of the study had a greater free water increase than patients who remained at the same stage, suggesting the change reflected Parkinsons-related damage to neurons.
Parkinsons disease destroys dopamine-producing cells in the substantia nigra, which connect to adjacent brain areas. Dr. Vaillancourts study showed that a greater free water increase in the substantia nigra was associated with a decrease in dopamine neuron activity in one of these nearby regions, supporting the idea that free water changes are related to progression of the disease.
That correlation is encouraging because it pins down the biological relevance of free water, Dr. Vaillancourt said.
The studys results suggest that the MRI-based free water measurement could be used in Parkinsons disease clinical trials. If a treatment slows or stops the increase in free water, it might be evidence that the drug is slowing the progressive loss of dopamine neurons.
The researchers used data from the Parkinsons Progression Markers Initiative (PPMI), a large study sponsored by the Michael J. Fox Foundation that has been collecting information on recently diagnosed Parkinsons patients from over 30 different U.S. and international sites. The fact that Dr. Vaillancourts team found similar patterns in patients at every location boosted his confidence in the results because, like the PPMI, clinical trials must collect data from many sites using numerous different MRI machines.
The PPMI data is real-world messy data, and when you find the effect in real-world messy data, it makes you think that it has legs, he said.
Dr. Vaillancourt speculated that his teams free water approach could make clinical trials less expensive by reducing the number of participants they would need to enroll. His team is currently running just such a study using free water to gauge the effect of a potential Parkinsons treatment. At the same time, the group is attempting to develop computer programs that will make free water analysis faster and easier. Future studies are needed to track changes in free water over longer time spans and in other brain regions and to determine what causes them.
The study was funded by NINDS (NS052318), the National Institute of Mental Health (MH108574), the National Institute of Biomedical Imaging and Bioengineering (EB015902), and the Parkinsons Progression Markers Initiative.
The NINDS (http://www.ninds.nih.gov) is the nations leading funder of research on the brain and nervous system.The mission of NINDS is to seek fundamental knowledge about the brain and nervous system and to use that knowledge to reduce the burden of neurological disease.
The mission of the National Institute of Mental Health (NIMH) is to transform the understanding and treatment of mental illnesses through basic and clinical research, paving the way for prevention, recovery and cure. For more information, visit http://www.nimh.nih.gov.
The mission of the National Institute of Biomedical Imaging and Bioengineering (NIBIB) is to improve health by leading the development and accelerating the application of biomedical technologies. The Institute is committed to integrating the physical and engineering sciences with the life sciences to advance basic research and medical care. For more information about the NIBIB, visit https://www.nibib.nih.gov/.
About the National Institutes of Health (NIH): NIH,the nation's medical research agency,includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services.NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research,and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov.
About the National Institutes of Health (NIH):NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov.
NIHTurning Discovery Into Health
Reference:Burciu et al. Progression marker of Parkinsons disease: a 4-year multi-site imaging study. Brain. July 26, 2017. doi: 10.1093/brain/awx146
- How a Parkinson's Protein Wreaks Havoc in the Brain - Technology Networks - February 15th, 2020
- Parkinsons: Innovative method stops toxic protein buildup - Medical News Today - February 15th, 2020
- Parkinson's driven by inflammation, genetics and the environment - UAB News - February 15th, 2020
- PARKINSON: Prepare for the moment; its never what it once was - Sarasota Herald-Tribune - February 15th, 2020
- The Neuroprotective Effects of Lithium - Psychiatric Times - February 15th, 2020
- Parkinsons Disease Treatment Market 2019- Global Industry Analysis, by Key Players, Segmentation, Application, Demand and Forecast by 2025 - Instant... - February 15th, 2020
- Biomarkers pave way for blood test to predict Parkinson's progression - New Atlas - February 15th, 2020
- Parkinson's Disease Treatment Market 2019 Analysis by Key Players, Share, Trend, Segmentation and Forecast to 2026 - Instant Tech News - February 15th, 2020
- Upcoming events Avadel takes on Jazz and Axovant awaits early results - Vantage - February 15th, 2020
- Are stem cells really the key to making humans live longer? - Wired.co.uk - February 15th, 2020
- VistaGen Therapeutics Reports Fiscal 2020 Third Quarter Financial Results and Provides CNS Pipeline Overview - Yahoo Finance - February 15th, 2020
- GB Sciences Announces Outstanding Results from Preclinical Study of Its Parkinson's Disease Formulations - PRNewswire - December 21st, 2019
- Dysarthria: Types, causes, and treatment - Medical News Today - December 21st, 2019
- Could Our Microbiome Treat Mental Disease and Other Illnesses? - Psychology Today - December 21st, 2019
- Parkinson's Disease Treatment Market Growth Rate by 2026 Top Key Vendors, Trend, Segmentation, Drivers, Challenges and Forecast - Testifyandrecap - December 21st, 2019
- Answer ALS Project to Better Understand and Treat Disease Moves into New Phase - ALS News Today - December 21st, 2019
- Parkinson's symptoms are improved with weekly regimens that include physical and cognitive exercises - PharmiWeb.com - December 21st, 2019
- Sleeping difficulty: Causes, treatments, and more - Medical News Today - December 21st, 2019
- Study Finds Antibodies That Reduce Parkinson's Alpha-synuclein Clumps - Parkinson's News Today - December 19th, 2019
- Things Lost and Things Gained - Parkinson's News Today - December 19th, 2019
- New Gene Therapy Method May Open BRAVE New World in Parkinson's - Parkinson's News Today - December 19th, 2019
- Aspen Neuroscience Receives $6.5M for Parkinson's Stem Cell Therapy - Parkinson's News Today - December 19th, 2019
- Could It Be the Pseudobulbar Affect or Am I Just Happy? - Parkinson's News Today - December 19th, 2019
- Caregivers of Patients With Recurrent Symptoms of Parkinson Disease Exposed to Greater Financial Burden, Loss of Employment - AJMC.com Managed Markets... - December 19th, 2019
- Oliver Sacks: A Bequest of Empathy and Candor - East Hampton Star - December 19th, 2019
- Aspen Neuroscience gets funding to pursue personalized cell therapy for Parkinsons disease - The San Diego Union-Tribune - December 15th, 2019
- How dance fights depression, Parkinson's, and other brain disease - Quartz - December 15th, 2019
- Experts Find Connection Between Parkinson's Treatment and Ability to Swim - SwimSwam - December 15th, 2019
- Devices to Record the Progression of PD - Parkinson's News Today - December 15th, 2019
- By turning stem cells into brain cells, Aspen Neuroscience hopes to rewind the progress of Parkinson's disease - FierceBiotech - December 15th, 2019
- Cerevance's Phase 2 Trial Recruiting PD Patients to Test CVN424 Therapy for Motor Symptoms - Parkinson's News Today - December 15th, 2019
- Seborrheic dermatitis hair loss: Causes and treatment - Medical News Today - December 15th, 2019
- Intec battered as Novartis ducks out of Accordion collaboration - PMLiVE - December 15th, 2019
- Retired Priest Allegedly Kills Teacher In Hit-And-Run, Blames Parkinson's Medication And 2 Drinks - Oxygen - December 15th, 2019
- BC woman describes state-of-the-art Parkinson's treatment as 'miraculous' - Coast Mountain News - December 6th, 2019
- Parkinson's Changes the Rules: It's OK to Ask for Help - Parkinson's News Today - December 6th, 2019
- I've Made BIG Improvements with Parkinson's Therapy Program - Parkinson's News Today - December 6th, 2019
- Managing the Cost of Chronic Illness - Parkinson's News Today - December 6th, 2019
- Screening Software for Parkinson's the Focus of New Collaboration - Parkinson's News Today - December 6th, 2019
- Treating multiple sclerosis with the help of the gut microbiome - FierceBiotech - December 6th, 2019
- Parkinson's disease treatment Market Size Global Projections, Industry Analysis, Size, Share 2019 Report - The Market Stats News - December 6th, 2019
- Parkinson's Disease Treatment Market 2019 Industry Outlook, Comprehensive Insights, Growth and Forecast 2025 - BoundWatch - December 6th, 2019
- Intra-Cellular Therapies to Present Data on Lumateperone and ITI-333 at the 58th Annual Meeting of the American College of Neuropsychopharmacology -... - December 6th, 2019
- Parkinson's Patients are Mysteriously Losing the Ability to Swim After Treatment - Discover Magazine - November 28th, 2019
- NDA for On-Demand Treatment of OFF Episodes in Parkinson Disease Resubmitted - Monthly Prescribing Reference - November 28th, 2019
- Finger twitching: 9 causes and when to see a doctor - Medical News Today - November 28th, 2019
- Does Parkinson's Start in the Brain or the Gut? - PsychCentral.com - November 28th, 2019
- Time to Try Again: Gene-Based Therapy for Neurodegeneration - Alzforum - November 28th, 2019
- Parkinson's Disease Treatment Market Analysis, Growth Rate, Overview, Market Segmentation and Forecast By 2024 - The Charterian - November 28th, 2019
- ACADIA Pharmaceuticals Announces Positive Top-line Results from ADVANCE Trial of Pimavanserin as Treatment for Negative Symptoms of Schizophrenia -... - November 28th, 2019
- Parkinsons disease symptoms: The sign in your handwriting to watch out for - Express - November 22nd, 2019
- Human Participants In Experimentation On The Brain? They Better Be Treated Well. - Forbes - November 22nd, 2019
- Smelling a cure for Parkinsons - Journal of the San Juan Islands - November 22nd, 2019
- Causes of Brain Inflammation in Parkinson's Can Be Visualized with Tiny Crystals, Study Reports - Parkinson's News Today - November 22nd, 2019
- Parkinson's Disease Treatments Market Growth Forecast Analysis by Top Manufacturers, Regions, Product Types and Application (2019 - 2026) - News... - November 22nd, 2019
- Newron Receives FDA Rare Pediatric Disease Designation for Sarizotan for the Treatment of Rett Syndrome - Business Wire - November 22nd, 2019
- Nebraska City hospital one of only 16 in U.S. offering incisionless treatment for tremors - Omaha World-Herald - November 18th, 2019
- The NHS is facing shortages of lifesaving treatments, says internal document - PMLiVE - November 18th, 2019
- Global Parkinson's Disease Treatment Market 2019 Business Prospects GSK, Merck, Novartis, Teva, Boehringer Ingelheim, Impax, Abbvie, Bausch Health -... - November 18th, 2019
- Axovant Gene Therapies Receives Orphan Drug Designation from FDA for AXO-AAV-GM1 for the Treatment of GM1 Gangliosidosis - BioSpace - November 18th, 2019
- Parkinson's Foundation Gives $250K for Parkinson's UK Treatment Project - Parkinson's News Today - November 15th, 2019
- Don't Worry, Be Happy: Parkinson's and the Limits of Positive Thinking - Parkinson's News Today - November 15th, 2019
- Study Reveals Factors That Contribute to Parkinson's-related Mortality - Parkinson's News Today - November 15th, 2019
- Why do many people with Parkinson's disease develop an addiction? We built a virtual casino to find out - The Conversation AU - November 15th, 2019
- Treating Opioid Addiction with Deep Brain Stimulation - Managed Care magazine - November 15th, 2019
- Can You Be a Rainmaker and Bring Hope to Dry Places? - Parkinson's News Today - November 15th, 2019
- resTORbio Announces That the Phase 3 PROTECTOR 1 Trial of RTB101 in Clinically Symptomatic Respiratory Illness Did Not Meet the Primary Endpoint -... - November 15th, 2019
- Doctors and patients excited as UI researchers start trials to treat Parkinson's - kwwl.com - November 12th, 2019
- Here's a Primer on Common Parkinson's Terms and Abbreviations - Parkinson's News Today - November 12th, 2019
- Deep brain stimulation may offer a new tool to fight opioid addiction - PhillyVoice.com - November 12th, 2019
- URI professor gets $250K grant for smart glove that could help patients with Parkinson's - The Westerly Sun - November 12th, 2019
- Prevail Therapeutics Reports Third Quarter 2019 Financial Results and Recent Business Highlights - GlobeNewswire - November 12th, 2019
- Parkinson's Disease and Your Bladder - University of Michigan Health System News - November 12th, 2019
- Study to Test Brain's 'Plumbing System' in Parkinson's, Alzheimer's - Parkinson's News Today - November 12th, 2019
- Gaucher Patients Want to Be Informed at Diagnosis of Parkinson's Risk, Study Reports - Gaucher Disease News - November 12th, 2019
- What's That Smell? What You Need to Know About Hyperosmia - Health Essentials from Cleveland Clinic - November 12th, 2019
- Making a difference in the treatment and prevention of Alzheimers Disease - WJBF-TV - November 12th, 2019
- NJ has one of the highest Parkinson's Disease rates in the nation - New Jersey 101.5 FM Radio - November 12th, 2019
- Weill Neurohub will fuel race to find new treatments for brain disease - UC Berkeley - November 12th, 2019
- ACADIA Pharmaceuticals to Host Investor Event and Webcast From Clinical Trials on Alzheimer's Disease (CTAD) Meeting on December 4, 2019 - Business... - November 12th, 2019